Physician Views: Are digital therapies for ADHD getting physicians’ attention?

Full data from the STARS-Adjunct study of Akili Interactive’s EndeavorRx digital therapeutic for attention deficit hyperactivity disorder (ADHD) have just come out. This set of results will be added to a growing body of evidence to support commercialisation of EndeavorRx, which kicked off in earnest after the digital therapeutic became the first of its kind to be cleared by the US FDA for treating ADHD.

While our previous poll noted rising levels of digital therapeutics adoption in medical practice, how aware are physicians of this new category of therapy entering the drug-dominant ADHD space? And how do physicians view newer, app-based approaches like EndeavorRx against other non-drug digitised therapies like neurostimulation?

We are conducting a snap-poll to physicians in the US and Europe to assess their attitudes to digital therapies for ADHD. Our questions are as follows:


Q1: On what % of your paediatric patients who have been diagnosed with attention deficit hyperactivity disorder (ADHD) do you prescribe medication as first-line treatment?


Q2: On what % of your paediatric ADHD patients who are receiving medication for their condition do you also recommend the use of a non-drug adjunct therapy (including neurostimulation technologies and digital app-based interventions)?


Q3: On a scale of 1 to 5 (1=no knowledge 5=highly knowledgeable), rate your level of knowledge about neurostimulation-based technologies for ADHD, for example, Monarch eTNS system by Neurosigma (external trigeminal nerve stimulation therapy)?


Q4: On a scale of 1 to 5 (1=no knowledge 5=highly knowledgeable), rate your level of knowledge about app-based, digital therapeutics for ADHD, for example, EndeavorRx by Akili Interactive (video game-based digital therapy)?


Q5: Akili Interactive’s EndeavorRx became the first video-game based therapy to be cleared by the US FDA in June last year. One study, STARS-Adjunct, found significant efficacy of EndeavorRx as a standalone therapy (change in impairment rating score (IRS) from baseline was −0.5, p < 0.001) and also significant efficacy of EndeavorRx as an adjunct to pharmacotherapy (change in IRS from baseline was  −0.7, p < 0.001).

Another study, the STARS-ADHD randomised controlled trial, compared EndeavorRx against a digital control intervention. It found a significant improvement in the composite attention functioning score in the treatment group (change in score 0.93) versus control group (change in score 0.03).

Based on these top-line findings, how do you see yourself integrating this digital therapeutic into the treatment protocol for ADHD patients?


Physician Views Results articles are available for free to FirstWord HealthTech PLUS subscribers. For more info, please contact

Did you like this article?